Friday, 27 May 2022
  
Login

Australia's most trusted
source of pharma news

Friday, 27 May 2022
News

Merck pips Novartis in MET race

Posted 21 January 2022 PM

Competition in the MET inhibitor space for non-small cell lung cancer (NSCLC) is heating up in Australia with Merck's Tepmetko finally provisionally approved this week as Novartis closes in with its candidate.

The TGA has granted Tepmetko provisional approval for the treatment of adult patients with locally advanced or metastatic NSCLC harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (9)

Sales & Customer Relations (38)

Access & Reimbursement (4)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (5)

Devices (2)

Other (28)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.